Book a free consultation
A no-obligation conversation with our care team, arranged through KPCIRC.
Book a consultationTurn existing data into a decision
Decipher
Already tested elsewhere? We turn data you already have into a full Blueprint Care decision, with no new sequencing.
01Turn existing data into a decision
Already tested elsewhere?
Decipher turns data you already have into a full Blueprint Care decision, with no new sequencing. We run your existing genomic report through our engine and KPCIRC sign-out.
You get the ranked plan, the trial matches, the biosimilar and access mapping, and the six intelligence layers, built on the test you already paid for.
0new samples needed
6intelligence layers applied
1signed decision
Image placeholder
An old report becoming a new plan
02
When it is right
You have a variant list
A recent comprehensive report, but no decision attached.
You want a deeper read
A second, more thorough interpretation and a signed plan.
You want to avoid re-testing
No cost or delay where re-sequencing is not needed.
03
Decipher or Decipher Plus?
| Decipher | Decipher Plus | |
|---|---|---|
| What we do | Interpret your existing data in full | Interpret, and fill only the missing pieces |
| New testing | None | A targeted top-up only, such as TMB, MSI or PGx |
| Best when | Your report is comprehensive | Your report is missing markers |
| Output | Full Blueprint Care report | Full Blueprint Care report |
04
How it works
- Step 1Share your report
Send us your existing genomic results.
- Step 2We assess completeness
We identify whether anything essential is missing.
- Step 3Interpret, and top up if needed
Decipher reads as-is. Plus adds the gaps first.
- Step 4KPCIRC sign-out
You receive a full, signed decision.
05
Quality in, quality out
We will not present an incomplete picture as a complete one.
Decipher can only interpret what your existing data contains. If your report is missing markers we will recommend Decipher Plus rather than fill the gap with guesswork.
Being clear about our limits
What we do and do not do
What we DO
- Re-annotate every alteration against current knowledge
- Apply all six intelligence layers and match trials, biosimilars and access
- Return a complete, tumour-board-signed decision
- Tell you honestly when your data is not complete enough
What we DON’T do
- Diagnose or decide treatment on its own
- Interpret markers your original report never measured
- Present an incomplete picture as complete
- Guarantee drug availability, approval, cover or benefit
Plain-language glossary (4 terms)
| Term | What it means |
|---|---|
| Interpretation | Turning an existing variant list into a ranked, evidenced decision. |
| Top-up | A small, targeted test to fill one missing marker such as TMB, MSI or PGx. |
| MTB | Molecular tumour board, the licensed panel that signs the final decision. |
| VUS | Variant of uncertain significance, a change whose meaning is not yet clear. |
Important information and regulatory status
Decipher and Decipher Plus is a genomic (DNA-based) test for use by qualified healthcare professionals. It supports clinical judgement, it does not replace it, and it must be read alongside your full clinical history and applicable guidelines.
- A result is not a diagnosis and does not by itself decide treatment.
- A “not detected” result does not rule out cancer or a genetic change.
- Not all cancers release enough DNA into blood to be detected.
- We cannot guarantee that a medicine will be available, approved, covered or effective.
- Collection kits are for qualified phlebotomists. They are not for self-testing.
- Confirmatory testing may be required.
Regulatory status (India). Registration of our genomic tests as in-vitro diagnostic (IVD) medical devices with CDSCO is in progress, with the IVD class pending. Sequencing and variant calling are done by an accredited laboratory partner (CAP-accredited, ISO 15189) following ACMG/AMP/ASCO/CAP guidelines and a CE-IVD certified variant database. The OnKommon interpretation engine is provided for research and decision-support use. Marketing follows the Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954.
Take the next step
Three ways forward. Pick the one that fits today.
Begin Blueprint Care
Commission your decision report and a dedicated clinical team.
Explore Blueprint CareAsk on WhatsApp, free
Signal replies to your first question within four hours, at no cost.
Start with Signal